{{Rsnum
|rsid=389719
|Chromosome=5
|position=27957331
|Orientation=plus
|GMAF=0.3122
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 66.4 | 32.7 | 0.9
| HCB | 29.9 | 53.3 | 16.8
| JPT | 29.2 | 55.8 | 15.0
| YRI | 61.2 | 31.3 | 7.5
| ASW | 52.6 | 38.6 | 8.8
| CHB | 29.9 | 53.3 | 16.8
| CHD | 34.9 | 43.1 | 22.0
| GIH | 54.5 | 38.6 | 6.9
| LWK | 77.3 | 19.1 | 3.6
| MEX | 19.0 | 51.7 | 29.3
| MKK | 70.5 | 26.9 | 2.6
| TSI | 52.9 | 43.1 | 3.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs389719
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: A, MAF= 0.25, combined P value= 2.01E-05.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470167
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs389719
|overall_frequency_n=38
|overall_frequency_d=128
|overall_frequency=0.296875
|n_genomes=25
|n_genomes_annotated=0
|n_haplomes=32
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}